Disseminated Aspergillosis following Allogeneic Hematopoietic Stem Cell Transplantation in an Acute Leukemic Patient who was Previously Treated for Invasive Aspergillosis.
- Author:
Ki Sun BAE
1
;
Ji Young PARK
;
Sue Yeun SHIN
;
Yeung Chul MUN
;
Hee Jung CHOI
;
Min Sun CHO
;
Chu Myong SEONG
Author Information
1. Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea. heechoi@ewha.ac.kr
- Publication Type:Case Report
- Keywords:
Aspergillosis;
Leukemia;
Stem cell transplantation
- MeSH:
Adult;
Amphotericin B;
Aspergillosis*;
Drug Therapy;
Endocarditis;
Female;
Hematopoietic Stem Cell Transplantation*;
Hematopoietic Stem Cells*;
Humans;
Immunocompromised Host;
Incidence;
Leukemia;
Leukemia, Myeloid, Acute;
Lung;
Mortality;
Prognosis;
Stem Cell Transplantation
- From:
Infection and Chemotherapy
2003;35(4):221-225
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Invasive aspergillosis has been increasing as the number of severe immunocompromised hosts rises. Particularly, in allogeneic hematopoietic stem cell transplantation (HSCT) recipients, incidence of invasive aspergillosis ranges from 4 to 10%. Even with appropriate treatment, the prognosis of invasive aspergillosis in allogeneic HSCT recipients remains poor, showing high mortality rate. Herein, we report a case where invasive aspergillosis in a patient with acute myelogeneous leukemia progressed to disseminated aspergillosis after allogeneic HSCT. A 31-year-old woman with acute myelogenous leukemia had invasive aspergillosis after third reinduction chemotherapy. After administering amphotericin B, the patient underwent the wedge resection of lung, and HLA-matched allogeneic HSCT was then conducted. On day 14 of transplantation, the patient died of disseminated aspergillosis, including possible cerebritis and endocarditis despite the amphotericin B therapy.
